Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Medigus Ltd is a medical devices business based in the US. Medigus shares (MDGS) are listed on the NASDAQ and all prices are listed in US Dollars. Medigus employs 20 staff and has a trailing 12-month revenue of around USD$202,000.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$0.83 - USD$5.15 |
---|---|
50-day moving average | USD$2.8915 |
200-day moving average | USD$2.119 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.78 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$202,000 |
---|---|
Gross profit TTM | USD$-182,000 |
Return on assets TTM | -25.58% |
Return on equity TTM | -160.71% |
Profit margin | 0% |
Book value | $31.82 |
Market capitalisation | USD$54.7 million |
TTM: trailing 12 months
There are currently 85,769 Medigus shares held short by investors – that's known as Medigus's "short interest". This figure is 35.9% up from 63,130 last month.
There are a few different ways that this level of interest in shorting Medigus shares can be evaluated.
Medigus's "short interest ratio" (SIR) is the quantity of Medigus shares currently shorted divided by the average quantity of Medigus shares traded daily (recently around 4.3 million). Medigus's SIR currently stands at 0.02. In other words for every 100,000 Medigus shares traded daily on the market, roughly 20 shares are currently held short.
However Medigus's short interest can also be evaluated against the total number of Medigus shares, or, against the total number of tradable Medigus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medigus's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Medigus shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Medigus shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medigus.
Find out more about how you can short Medigus stock.
We're not expecting Medigus to pay a dividend over the next 12 months.
Medigus's shares were split on a 1:4 basis on 16 July 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Medigus shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Medigus shares which in turn could have impacted Medigus's share price.
Over the last 12 months, Medigus's shares have ranged in value from as little as $0.83 up to $5.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medigus's is 2.5032. This would suggest that Medigus's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.